Navigation Links
Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
Date:1/23/2013

companies that are seeking to market generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential introduction of unauthorized generic competition to OFIRMEV in the event Cadence is unsuccessful in current or future patent litigation; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous federal, state and local laws and regulatory requirements that apply to its commercial activities; public concern regarding the safety of drug products such as OFIRMEV, which could result in the implementation by regulatory agencies of new requirements to include unfavorable information in the labeling for OFIRMEV; the risk that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc. Contact:

William R. LaRueKelli FranceSVP & Chief Financial OfficerMedia RelationsCadence Pharmaceuticals, Inc.WCGPhone: 858-436-14Phone: 415-946-1076


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
2. Cadence Pharmaceuticals to Host Analyst and Investor Day
3. Cadence to Open Finished Medical Device Facility
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
5. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
7. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
8. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
9. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
10. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
11. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at ... is the first in Loudoun County to ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian ... Cole Taylor , are avid scuba divers. "As altitude skiers and ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Three Independent Clinical Trials Initiated with Teplizumab Manufactured at ... ... that its Protege trial is actively enrolling adults and children ages,8 to ... evaluate the safety and efficacy of three teplizumab dosing,regimens administered at the ...
... versus 26.2 for ... Vidaza compared to ... conventional ... modifier to show survival benefit in cancer Stratified log-rank p-value = 0.0001, Hazard ...
Cached Medicine Technology:MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 2MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 3MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 2Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 3Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 5Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 6Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 7Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 8
(Date:7/9/2014)... common type of lung cancer, researchers have uncovered mutations ... forming tumors. The new knowledge may expand treatments for ... already are available or are in clinical trials. , ... The Cancer Genome Atlas (TCGA), including researchers at Washington ... School and other institutions, studied tumors from 230 patients ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2
... to debate on the supplement but doesn,t settle it, one ... Glucosamine sulfate, a popular dietary supplement purported to ease the ... people with arthritis in their hips. , That,s the conclusion ... a placebo for the treatment of mild to moderate hip ...
... named the,fastest growing PR agency in the U.S., announced ... Symposium," showcasing exclusive consumer,brands from 5W,s Health & Beauty ... April 22nd from 10 a.m. to 2 p.m. at ... Hearst building and near the Time,Warner Center., This ...
... to Industry Best-Practices, MINNEAPOLIS, Feb. ... established national healthcare consulting practice, has ... which a PBM or Health,Plan can ... core organizational quality, customer service, communications ...
... Radiology Group (FRG),and the Brownsville Tri-County Hospital have ... Brownsville,s exclusive provider of,diagnostic imaging services., "The ... work,with," stated Richard W. Hritz, CEO of the ... involvement in working to bring this,hospital back online, ...
... 18 In rural Milledgeville,Georgia, 62 year old insulin-dependent ... 10,000+ mile perimeter walk of the United,States raising awareness ... "I,ve hit milestones in San Diego, Seattle, Chicago, Boston, ... of diabetes, only,fewer resources to manage it. We can ...
... Feb. 18 Be aware, be,prepared and take ... State University trauma expert on,preventing tragedies like the ... Briana Nelson Goff, associate dean of K-State,s College ... and human services,leads the Trauma Research, Education and ...
Cached Medicine News:Health News:Study Suggests Glucosamine Won't Ease Hip Arthritis 2Health News:Study Suggests Glucosamine Won't Ease Hip Arthritis 3Health News:5W Public Relations Hosts Exclusive Beauty & Wellness Industry Event 2Health News:Halleland Health Consulting Assists PBMs in Achieving URAC Accreditation for Pharmacy Benefit Management 2Health News:Foundation Radiology Group and Brownsville Tri-County Hospital Sign Long-Term Contract for Diagnostic Imaging Services 2Health News:Foundation Radiology Group and Brownsville Tri-County Hospital Sign Long-Term Contract for Diagnostic Imaging Services 3Health News:Mr. Diabetes(R) Hits 9,000 Mile Mark of 10,000+ Mile Walk to Raise Awareness About Diabetes 2Health News:K-State Trauma Researcher Says Being Prepared, Taking Action Are Vital in Preventing Tragedies Like the One at NIU 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: